Azaphenylalanine-based serine protease inhibitors induce caspase-mediated apoptosis

European Journal of Pharmacology

Volumn 602, Issue 1, 2009, Pages 15-22

  Celhar, Teja ^a   Napotnik, Tina Batista ^a   Obreza, Ales ^a   Zega, Anamarija ^a   Anderluh, Petra Stefanic ^a   Kikelj, Danijel ^a   Mlinaric Rascan, Irena ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Anticancer drug; Apoptosis; Serine protease; Serine protease inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; AZAPHENYLALANINE DERIVATIVE; BLOOD CLOTTING FACTOR 10; CASPASE; CHYMOTRYPSIN; FIBRINOGEN RECEPTOR ANTAGONIST; LEUKOCYTE ELASTASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBIN INHIBITOR; TOSYLLYSYL CHLOROMETHYL KETONE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL DEATH; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG INHIBITION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LYMPHOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL;

APOPTOSIS; CASPASES; CELL LINE, TUMOR; HUMANS; LYMPHOMA, B-CELL; PHENYLALANINE; SERINE PROTEINASE INHIBITORS; TIME FACTORS;

EID: 57249109873     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.11.008     Document Type: Article

References (40)

1. Abbenante G., and Fairlie D.P. Protease inhibitors in the clinic. Med. Chem. 1 (2005) 71-104
2. Adams J., and Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investig. 22 (2004) 304-311
3. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., and Yuan J. Human ICE/CED-3 protease nomenclature. Cell 87 (1996) 171
4. Bories D., Raynal M.C., Solomon D.H., Darzynkiewicz Z., and Cayre Y.E. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59 (1989) 959-968
5. Bröker L.E., Kruyt F.A., and Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 11 (2005) 3155-3162
6. Chipuk J.E., and Green D.R. Do inducers of apoptosis trigger caspase-independent cell death?. Nat. Rev., Mol. Cell Biol. 6 (2005) 268-275
7. Delaria K.A., Muller D.K., Marlor C.W., Brown J.E., Das R.C., Roczniak S.O., and Tamburini P.P. Characterization of placental bikunin, a novel human serine protease inhibitor. J. Biol. Chem. 272 (1997) 12209-12214
8. Eitel K., Wagenknecht B., and Weller M. Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. Cancer Lett. 142 (1999) 11-16
9. Elmore S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (2007) 495-516
10. Fearnhead H.O., MacFarlane M., Dinsdale D., and Cohen G.M. DNA degradation and proteolysis in thymocyte apoptosis. Toxicol. Lett. 82-83 (1995) 135-141
11. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev., Cancer 5 (2005) 876-885
12. Fischer U., and Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 12 (2005) 942-961
13. Hara S., Halicka H.D., Bruno S., Gong J., Traganos F., and Darzynkiewicz Z. Effect of protease inhibitors on early events of apoptosis. Exp. Cell Res. 223 (1996) 372-384
14. Hedstrom L. Serine protease mechanism and specificity. Chem. Rev. 102 (2002) 4501-4523
15. Jaulent A.M., and Leatherbarrow R.J. Design, synthesis and analysis of novel bicyclic and bifunctional protease inhibitors. Protein Eng. Des. Sel. 17 (2004) 681-687
16. Johnson D.E. Noncaspase proteases in apoptosis. Leukemia 14 (2000) 1695-1703
17. King M.A., Halicka H.D., and Darzynkiewicz Z. Pro- and anti-apoptotic effects of an inhibitor of chymotrypsin-like serine proteases. Cell Cycle 3 (2004) 1566-1571
18. Kroemer G., and Martin S.J. Caspase-independent cell death. Nat. Med. 11 (2005) 725-730
19. Kumar S. Caspase function in programmed cell death. Cell Death Differ. 14 (2007) 32-43
20. Lankiewicz S., Marc Luetjens C., Truc Bui N., Krohn A.J., Poppe M., Cole G.M., Saido T.C., and Prehn J.H. Activation of calpain I converts excitotoxic neuron death into a caspase-independent cell death. J. Biol. Chem. 275 (2000) 17064-17071
21. Mlinaric-Rascan I., and Turk B. B cell receptor-mediated nuclear fragmentation proceeds in WEHI 231 cells in the absence of detectable DEVDase and FRase activity. FEBS Lett. 553 (2003) 51-55
22. Moffit K.L., Martin S.L., and Walker B. The emerging role of serine proteases in apoptosis. Biochem. Soc. Trans. 35 (2007) 559-560
23. Murn J., Urleb U., and Mlinaric-Rascan I. Internucleosomal DNA cleavage in apoptotic WEHI 231 cells is mediated by a chymotrypsin-like protease. Genes Cells 9 (2004) 1103-1111
24. Obreza A., Stegnar M., Trampus-Bakija A., Prezelj A., and Urleb U. Synthesis and in vitro evaluation of new azaphenylalanine derivatives as serine protease inhibitors. Pharmazie 59 (2004) 739-743
25. Obreza A., Stegnar M., and Urleb U. Novel non-covalent azaphenylalanine thrombin inhibitors with an aminomethyl or amino group at the P1 position. Pharmazie 59 (2004) 659-667
26. Reed J.C., and Tomaselli K.J. Drug discovery opportunities from apoptosis research. Curr. Opin. Biotechnol. 11 (2000) 586-592
27. Riedl S.J., and Shi Y. Molecular mechanism of caspase regulation during apoptosis. Nat. Rev., Mol. Cell Biol. 5 (2004) 897-907
28. Stein R.L. Catalysis by human leukocyte elastase: substrate structural dependence of rate-limiting protolytic catalysis and operation of the charge relay system. J. Am. Chem. Soc. 105 (1983) 5111-5116
29. Smolnikar I., Perdih A., Stegnar M., Prezelj A., Solmajer T., Urleb U., and Obreza A. Design, synthesis and molecular modelling of 1-amidinopiperidine thrombin inhibitors. Pharmazie 62 (2007) 243-254
30. Stefanic P., Simoncic Z., Breznik M., Plavec J., Anderluh M., Addicks E., Giannis A., and Kikelj D. Conformationally tailored N-[(2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)carbonyl]proline templates as molecular tools for the design of peptidomimetics. Design and synthesis of fibrinogen receptor antagonists. Org. Biomol. Chem. 2 (2004) 1511-1517
31. Stefanic Anderluh P., Anderluh M., Ilas J., Mravljak J., Sollner Dolenc M., Stegnar M., and Kikelj D. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities. J. Med. Chem. 48 (2005) 3110-3113
32. Stenson-Cox C., FitzGerald U., and Samali A. In the cut and thrust of apoptosis, serine proteases come of age. Biochem. Pharmacol. 66 (2003) 1469-1474
33. Thiemmara V., Pays L., Danty E., Jourdan F., Moyse E., and Mehlen P. Serine protease inhibitor Spi2 mediated apoptosis of olfactory neurons. Cell Death Differ. 9 (2002) 1343-1351
34. Verhagen A.M., Silke J., Ekert P.G., Pakush M., Kaufmann H., Connolly L.M., Day C.L., Tikoo A., Burke R., Wrobel C., Moritz R.L., Simpson R.J., and Vaux D.L. HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem. 277 (2002) 445-454
35. Wright S.C., Wei Q.S., Zhong J., Zheng H., Kinder D.H., and Larrick J.W. Purification of a 24-kD protease from apoptotic tumor cells that activates DNA fragmentation. J. Exp. Med. 180 (1994) 2113-2123
36. Wyllie A.H., Kerr J.F., and Currie A.R. Cell death: the significance of apoptosis. Int. Rev. Cyt. 68 (1980) 251-306
37. Zain J., Huang Y.Q., Feng X., Nierodzik M.L., Li J.J., and Karpatkin S. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 95 (2000) 3133-3138
38. Zapata J.M., Takahashi R., Salvesen G.S., and Reed J.C. Granzyme release and caspase activation in activated human T-lymphocytes. J. Biol. Chem. 273 (1998) 6916-6920
39. Zega A., Mlinsek G., Solmajer T., Trampus-Bakija A., Stegnar M., and Urleb U. Thrombin inhibitors built on azaphenylalanine scaffold. Bioorg. Med. Chem. Lett. 14 (2004) 1563-1567
40. Zhu H., Dinsdale D., Alnemri E.S., and Cohen G.M. Apoptosis in human monocytic THP.1 cells involves several distinct targets of N-tosyl-l-phenylalanyl chloromethyl ketone (TPCK). Cell Death Differ. 4 (1997) 590-599